I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Phase 1 study of the pan-RAF inhibitor tovorafenib in patie..:
Rasco, DW
;
Medina, T
;
Corrie, P
...
doi:10.1007/s00280-023-04544-5. , 2023
Link:
https://doi.org/10.1007/s00280-023-04544-5
RT Journal T1
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma
UL https://suche.suub.uni-bremen.de/peid=base-ftinstcancerres:oai:repository.icr.ac.uk:internal_5936&Exemplar=1&LAN=DE A1 Rasco, DW A1 Medina, T A1 Corrie, P A1 Pavlick, AC A1 Middleton, MR A1 Lorigan, P A1 Hebert, C A1 Plummer, R A1 Larkin, J A1 Agarwala, SS A1 Daud, AI A1 Qiu, J A1 Bozon, V A1 Kneissl, M A1 Barry, E A1 Olszanski, AJ PB SPRINGER YR 2023 K1 BRAF K1 Melanoma K1 Pan-RAF inhibitor K1 Phase 1 K1 Tovorafenib K1 Adult K1 Humans K1 Proto-Oncogene Proteins B-raf K1 Neoplasms K1 Skin Neoplasms K1 Protein Kinase Inhibitors K1 Second Primary K1 Mitogen-Activated Protein Kinase Kinases K1 Maximum Tolerated Dose JF doi:10.1007/s00280-023-04544-5 LK http://dx.doi.org/https://doi.org/10.1007/s00280-023-04544-5 DO https://doi.org/10.1007/s00280-023-04544-5 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)